Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CF-301 in S. aureus Bacteremia and Endocarditis
NCT03163446Phase 2Completed
- Sponsor
- ContraFect Corporation
- Start
- May 2017
- Primary completion
- Mar 2019
- Modality
- Therapeutic Enzymes
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial in Staphylococcus aureus bacteremia (SAB) and infective endocarditis (IE) comparing CF-301 + SOC with Placebo + SOC (2 arms). Primary endpoints: Incidence of Adverse Events at Day 180, Clinical Outcome at Day 14 and 2 more. Started May 2017; status: completed.
02
Drugs
exebacase
03
Conditions
Staphylococcus aureus bacteremia (SAB)infective endocarditis (IE)
Beyond the preview
Go deeper on NCT03163446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03163446.